Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01585870
Recruitment Status : Completed
First Posted : April 26, 2012
Last Update Posted : October 27, 2015
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2015
  Actual Study Completion Date : September 2015